Structure of recombinant Leishmania donovani pteridine reductase reveals a disordered active site

Keri L. Barrack, Lindsay B. Tulloch, Lynsey-Ann Burke, Paul K. Fyfe, William N. Hunter

    Research output: Contribution to journalArticle

    14 Citations (Scopus)

    Abstract

    Pteridine reductase (PTR1) is a potential target for drug development against parasitic Trypanosoma and Leishmania species, protozoa that are responsible for a range of serious diseases found in tropical and subtropical parts of the world. As part of a structure-based approach to inhibitor development, specifically targeting Leishmania species, well ordered crystals of L. donovani PTR1 were sought to support the characterization of complexes formed with inhibitors. An efficient system for recombinant protein production was prepared and the enzyme was purified and crystallized in an orthorhombic form with ammonium sulfate as the precipitant. Diffraction data were measured to 2.5 angstrom resolution and the structure was solved by molecular replacement. However, a sulfate occupies a phosphate-binding site used by NADPH and occludes cofactor binding. The nicotinamide moiety is a critical component of the active site and without it this part of the structure is disordered. The crystal form obtained under these conditions is therefore unsuitable for the characterization of inhibitor complexes.

    Original languageEnglish
    Pages (from-to)33-37
    Number of pages5
    JournalActa Crystallographica F-Structural Biology and Crystallization Communications
    Volume67
    DOIs
    Publication statusPublished - Jan 2011

    Keywords

    • DRUG-RESISTANCE
    • INHIBITORS
    • DESIGN
    • METABOLISM
    • DISCOVERY
    • COMPLEX
    • BINDING
    • TARGET
    • PTR1

    Cite this

    @article{d22dacdf61c24c898245f0088fe3a6d6,
    title = "Structure of recombinant Leishmania donovani pteridine reductase reveals a disordered active site",
    abstract = "Pteridine reductase (PTR1) is a potential target for drug development against parasitic Trypanosoma and Leishmania species, protozoa that are responsible for a range of serious diseases found in tropical and subtropical parts of the world. As part of a structure-based approach to inhibitor development, specifically targeting Leishmania species, well ordered crystals of L. donovani PTR1 were sought to support the characterization of complexes formed with inhibitors. An efficient system for recombinant protein production was prepared and the enzyme was purified and crystallized in an orthorhombic form with ammonium sulfate as the precipitant. Diffraction data were measured to 2.5 angstrom resolution and the structure was solved by molecular replacement. However, a sulfate occupies a phosphate-binding site used by NADPH and occludes cofactor binding. The nicotinamide moiety is a critical component of the active site and without it this part of the structure is disordered. The crystal form obtained under these conditions is therefore unsuitable for the characterization of inhibitor complexes.",
    keywords = "DRUG-RESISTANCE, INHIBITORS, DESIGN, METABOLISM, DISCOVERY, COMPLEX, BINDING, TARGET, PTR1",
    author = "Barrack, {Keri L.} and Tulloch, {Lindsay B.} and Lynsey-Ann Burke and Fyfe, {Paul K.} and Hunter, {William N.}",
    year = "2011",
    month = "1",
    doi = "10.1107/S174430911004724X",
    language = "English",
    volume = "67",
    pages = "33--37",
    journal = "Acta Crystallographica F-Structural Biology and Crystallization Communications",
    issn = "1744-3091",
    publisher = "International Union of Crystallography",

    }

    Structure of recombinant Leishmania donovani pteridine reductase reveals a disordered active site. / Barrack, Keri L.; Tulloch, Lindsay B.; Burke, Lynsey-Ann; Fyfe, Paul K.; Hunter, William N.

    In: Acta Crystallographica F-Structural Biology and Crystallization Communications, Vol. 67, 01.2011, p. 33-37.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - Structure of recombinant Leishmania donovani pteridine reductase reveals a disordered active site

    AU - Barrack, Keri L.

    AU - Tulloch, Lindsay B.

    AU - Burke, Lynsey-Ann

    AU - Fyfe, Paul K.

    AU - Hunter, William N.

    PY - 2011/1

    Y1 - 2011/1

    N2 - Pteridine reductase (PTR1) is a potential target for drug development against parasitic Trypanosoma and Leishmania species, protozoa that are responsible for a range of serious diseases found in tropical and subtropical parts of the world. As part of a structure-based approach to inhibitor development, specifically targeting Leishmania species, well ordered crystals of L. donovani PTR1 were sought to support the characterization of complexes formed with inhibitors. An efficient system for recombinant protein production was prepared and the enzyme was purified and crystallized in an orthorhombic form with ammonium sulfate as the precipitant. Diffraction data were measured to 2.5 angstrom resolution and the structure was solved by molecular replacement. However, a sulfate occupies a phosphate-binding site used by NADPH and occludes cofactor binding. The nicotinamide moiety is a critical component of the active site and without it this part of the structure is disordered. The crystal form obtained under these conditions is therefore unsuitable for the characterization of inhibitor complexes.

    AB - Pteridine reductase (PTR1) is a potential target for drug development against parasitic Trypanosoma and Leishmania species, protozoa that are responsible for a range of serious diseases found in tropical and subtropical parts of the world. As part of a structure-based approach to inhibitor development, specifically targeting Leishmania species, well ordered crystals of L. donovani PTR1 were sought to support the characterization of complexes formed with inhibitors. An efficient system for recombinant protein production was prepared and the enzyme was purified and crystallized in an orthorhombic form with ammonium sulfate as the precipitant. Diffraction data were measured to 2.5 angstrom resolution and the structure was solved by molecular replacement. However, a sulfate occupies a phosphate-binding site used by NADPH and occludes cofactor binding. The nicotinamide moiety is a critical component of the active site and without it this part of the structure is disordered. The crystal form obtained under these conditions is therefore unsuitable for the characterization of inhibitor complexes.

    KW - DRUG-RESISTANCE

    KW - INHIBITORS

    KW - DESIGN

    KW - METABOLISM

    KW - DISCOVERY

    KW - COMPLEX

    KW - BINDING

    KW - TARGET

    KW - PTR1

    U2 - 10.1107/S174430911004724X

    DO - 10.1107/S174430911004724X

    M3 - Article

    VL - 67

    SP - 33

    EP - 37

    JO - Acta Crystallographica F-Structural Biology and Crystallization Communications

    JF - Acta Crystallographica F-Structural Biology and Crystallization Communications

    SN - 1744-3091

    ER -